表紙
市場調査レポート

世界の心房細動治療市場

Global Atrial Fibrillation Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 232658
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の心房細動治療市場 Global Atrial Fibrillation Market 2015-2019
出版日: 2015年01月28日 ページ情報: 英文 67 Pages
概要

世界における心房細動治療市場は、世界的に人口の高齢化が進むことなどを背景に、2014年から2019年かけて、11.05%のCAGRで拡大することが予測されています。

当レポートでは、世界における心房細動治療市場を調査しており、これらの市場の動向と成長の見通し、主要ベンダーの分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 製品プロファイル

  • Pradaxa/ Prazaxa
  • Xarelto
  • Multaq

第5章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第6章 イントロダクション

第7章 疾患の概要

  • 疾患の理解
  • 分類
  • 病態生理学
  • 原因
  • 疫学
  • 管理
  • 経済的負担

第8章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 薬剤クラス別の市場分類

  • 坑凝固薬
  • 抗不整脈薬

第10章 地理区分

第11章 購入基準

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Boehringer Ingelheim
    • Sanofi
    • Janssen Pharmaceuticals
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Sanofi

第20章 関連レポート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR5053

About Atrial Fibrillation

According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

TechNavio's analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Atrial Fibrillation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Sanofi

Other Prominent Vendors

  • ARCA Biopharma
  • Armetheon
  • Baxter
  • Bristol-Myers Squibb
  • ChanRx
  • Daiichi Sankyo
  • Gilead Sciences
  • HUYA Biosciences
  • Menarini
  • Pfizer
  • Pierre Fabre
  • Servier
  • Xention

Market Driver

  • Growing Patient Base
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Market Trend

  • Shifting Focus on Emerging Markets
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Pradaxa/ Prazaxa
    • 04.1.2. Xarelto
    • 04.1.3. Multaq

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Classification
  • 07.3. Pathophysiology
  • 07.4. Causes
  • 07.5. Epidemiology
  • 07.6. Management
  • 07.7. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Class of Drugs

    • 09.1.1. Anticoagulants
    • 09.1.2. Anti-arrythmics

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Boehringer Ingelheim
    • 18.2.2. Sanofi
    • 18.2.3. Janssen Pharmaceuticals
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Boehringer Ingelheim
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2012 and 2013
    • 19.1.5. Geographical Segmentation by Revenue 2013
    • 19.1.6. Business Strategy
    • 19.1.7. Recent Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Janssen Pharmaceuticals
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Recent Developments
    • 19.2.4. SWOT Analysis
  • 19.3. Sanofi
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of Atrial Fibrillation
  • Exhibit 3: Risk Factors Associated with Atrial Fibrillation
  • Exhibit 4: Management of Atrial Fibrillation
  • Exhibit 5: Economic Burden of Atrial Fibrillation
  • Exhibit 6: Global Atrial Fibrillation Market 2014-2019 (US$ million)
  • Exhibit 7: Challenges and Drivers of Global Atrial Fibrillation Market
  • Exhibit 8: Global Atrial Fibrillation Market Segmentation by Class of Drugs
  • Exhibit 9: Sub-classification of Anti-arrythmics
  • Exhibit 10: Segmentation of Global Atrial Fibrillation Market by Geography 2014
  • Exhibit 11: Buying Criteria of the Global Atrial Fibrillation market
  • Exhibit 12: World's Population Aged 60 and Above (2010-2020)
  • Exhibit 13: The Global Prevalence of Atrial Fibrillation 2006-2016 (Million)
  • Exhibit 14: Drivers and their Impact on the Key Customer Category of the Global Atrial Fibrillation market
  • Exhibit 15: Drivers and their Impact on Geographies in Global Atrial Fibrillation Market
  • Exhibit 16: Global Atrial Fibrillation Market Share Analysis 2014
  • Exhibit 17: Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 18: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 20: Sanofi SA: Business Segmentation
  • Exhibit 21: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 22: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 23: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top